Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · Real-Time Price · USD
0.5822
+0.0195 (3.47%)
At close: Nov 13, 2026, 4:00 PM EST
0.5799
-0.0023 (-0.40%)
After-hours: Nov 13, 2026, 7:43 PM EST
Biomea Fusion Employees
Biomea Fusion had 37 employees as of June 30, 2026. The number of employees decreased by 26 or 41.27% compared to the same quarter last year. That makes Biomea Fusion the 36,371st largest employer in the world and 4,965th in the United States.
Employees
37
Change (1Y)
-26
Growth (1Y)
-41.27%
Revenue / Employee
n/a
Profits / Employee
-$603,081
Market Cap
42.20M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 37 | -26 | -41.27% |
| Mar 31, 2026 | 40 | -39 | -49.37% |
| Dec 31, 2025 | 41 | -65 | -61.32% |
| Sep 30, 2025 | 42 | -65 | -60.75% |
| Jun 30, 2025 | 63 | -49 | -43.75% |
| Mar 31, 2025 | 79 | -31 | -28.18% |
| Dec 31, 2024 | 106 | 3 | 2.91% |
| Sep 30, 2024 | 107 | 4 | 3.88% |
| Jun 30, 2024 | 112 | 18 | 19.15% |
| Mar 31, 2024 | 110 | 24 | 27.91% |
| Dec 31, 2023 | 103 | 20 | 24.10% |
| Sep 30, 2023 | 103 | 28 | 37.33% |
| Jun 30, 2023 | 94 | 22 | 30.56% |
| Mar 31, 2023 | 86 | 29 | 50.88% |
| Dec 31, 2022 | 83 | 32 | 62.75% |
| Sep 30, 2022 | 75 | 28 | 59.57% |
| Jun 30, 2022 | 72 | 52 | 260.00% |
| Mar 31, 2022 | 57 | 37 | 185.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Alps Group | 93 |
| Connect Biopharma Holdings | 64 |
| Pliant Therapeutics | 49 |
| IRulya Therapeutics | 38 |
| Elicio Therapeutics | 33 |
| Gain Therapeutics | 21 |
| ImageneBio | 18 |
| Instil Bio | 17 |
BMEA News
- 3 days ago - Biomea Fusion to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 5 days ago - Biomea Fusion reports Q3 EPS (9c), consensus (23c) - TheFly
- 5 days ago - Biomea Fusion Reports Third Quarter 2026 Financial Results and Corporate Highlights - GlobeNewsWire
- 5 days ago - Biomea Fusion Announces Poster Presentation of Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist, at ObesityWeek® 2026 - GlobeNewsWire
- 5 days ago - Biomea Fusion Quarterly report: Q3 2026 - Filings
- 5 days ago - Biomea Fusion Earnings release: Q3 2026 - Filings
- 4 weeks ago - Biomea Fusion Transcript: Study result - Transcripts
- 4 weeks ago - Biomea Fusion Press release: Study result - Filings